Regeneron-话题@MedSci - 梅斯（MedSci）

#Regeneron#

18篇内容 | 1260人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1968043, encodeId=f7d21968043a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=赛诺菲（Sanofi）和再生元（Regeneron）撤销关于Libtayo治疗宫颈癌的申请, objectType=article, longId=295109, objectId=a25b295109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a25b295109ad, replyNumber=0, likeNumber=145, createdTime=2022-04-13, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a25b295109ad, moduleTitle=赛诺菲（Sanofi）和再生元（Regeneron）撤销关于Libtayo治疗宫颈癌的申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a25b295109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968040, encodeId=78ec19680408e, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, objectType=article, longId=197185, objectId=861519e185ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=861519e185ee, replyNumber=0, likeNumber=103, createdTime=2021-01-08, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=861519e185ee, moduleTitle=Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=861519e185ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968042, encodeId=10701968042a1, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的COVID-19抗体“鸡尾酒”REGN-COV2可大幅减少病毒载量, objectType=article, longId=202648, objectId=434a2026480b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=434a2026480b, replyNumber=0, likeNumber=150, createdTime=2021-08-02, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=434a2026480b, moduleTitle=Regeneron的COVID-19抗体“鸡尾酒”REGN-COV2可大幅减少病毒载量, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=434a2026480b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968039, encodeId=b2f71968039b2, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法, objectType=article, longId=187513, objectId=217a18e513c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=217a18e513c4, replyNumber=0, likeNumber=153, createdTime=2020-09-27, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=217a18e513c4, moduleTitle=抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=217a18e513c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968041, encodeId=2de6196804193, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, objectType=article, longId=202130, objectId=a6d020213007, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6d020213007, replyNumber=0, likeNumber=86, createdTime=2021-09-22, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6d020213007, moduleTitle=Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a6d020213007)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968038, encodeId=341b1968038e7, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生, objectType=article, longId=186028, objectId=8a7a18602841, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a7a18602841, replyNumber=0, likeNumber=91, createdTime=2020-06-21, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a7a18602841, moduleTitle=Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8a7a18602841)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968037, encodeId=7242196803e30, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron和Vyriad宣布开发新的溶瘤病毒治疗癌症的战略协议, objectType=article, longId=182551, objectId=465e182551bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=465e182551bb, replyNumber=0, likeNumber=72, createdTime=2020-03-09, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=465e182551bb, moduleTitle=Regeneron和Vyriad宣布开发新的溶瘤病毒治疗癌症的战略协议, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=465e182551bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968035, encodeId=a625196803539, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, objectType=article, longId=174938, objectId=c1da1e4938eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c1da1e4938eb, replyNumber=0, likeNumber=125, createdTime=2019-11-30, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c1da1e4938eb, moduleTitle=英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c1da1e4938eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968034, encodeId=45f3196803454, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, objectType=article, longId=172193, objectId=f8e41e2193df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8e41e2193df, replyNumber=0, likeNumber=75, createdTime=2019-09-22, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8e41e2193df, moduleTitle=赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f8e41e2193df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968036, encodeId=d63c19680368e, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, objectType=article, longId=177716, objectId=cb201e7716eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb201e7716eb, replyNumber=0, likeNumber=148, createdTime=2020-04-13, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb201e7716eb, moduleTitle=Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=cb201e7716eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968033, encodeId=9e761968033dc, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变, objectType=article, longId=166172, objectId=80b21661e219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=80b21661e219, replyNumber=0, likeNumber=96, createdTime=2019-09-25, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=80b21661e219, moduleTitle=Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=80b21661e219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968032, encodeId=4301196803256, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron和Bluebird Bio强强联手助力于T细胞疗法, objectType=article, longId=146074, objectId=f21e1460e46b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21e1460e46b, replyNumber=0, likeNumber=0, createdTime=2018-11-29, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21e1460e46b, moduleTitle=Regeneron和Bluebird Bio强强联手助力于T细胞疗法, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f21e1460e46b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968031, encodeId=566e196803147, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=美国优先审查Sanofi，Regeneron的cemiplimab。, objectType=article, longId=136950, objectId=508213695093, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508213695093, replyNumber=0, likeNumber=109, createdTime=2018-11-04, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508213695093, moduleTitle=美国优先审查Sanofi，Regeneron的cemiplimab。, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=508213695093)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968030, encodeId=6a0e19680301e, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron和Teva的疼痛药物fasinumab被FDA暂时临床搁置, objectType=article, longId=80718, objectId=c00480e1889, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c00480e1889, replyNumber=0, likeNumber=77, createdTime=2017-03-20, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c00480e1889, moduleTitle=Regeneron和Teva的疼痛药物fasinumab被FDA暂时临床搁置, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=c00480e1889)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968029, encodeId=fab5196802915, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, objectType=article, longId=42968, objectId=df2042968c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2042968c5, replyNumber=0, likeNumber=137, createdTime=2015-06-25, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2042968c5, moduleTitle=赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df2042968c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968027, encodeId=b389196802e0c, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron公司药物Arcalyst扩大应用申请遭FDA拒绝, objectType=article, longId=8487, objectId=bccc848e83, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bccc848e83, replyNumber=0, likeNumber=90, createdTime=2012-11-22, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bccc848e83, moduleTitle=Regeneron公司药物Arcalyst扩大应用申请遭FDA拒绝, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=bccc848e83)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968026, encodeId=63441968026b7, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=Regeneron公司单抗药物REGN727稍逊于安进公司药物AMG145, objectType=article, longId=5401, objectId=be425401ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=be425401ed, replyNumber=0, likeNumber=71, createdTime=2012-11-03, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=be425401ed, moduleTitle=Regeneron公司单抗药物REGN727稍逊于安进公司药物AMG145, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=be425401ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1968028, encodeId=d6a0196802856, content=<a href='/topic/show?id=9e5e15269a8' target=_blank style='color:#2F92EE;'>#Regeneron#</a>, objectTitle=赛诺菲及Regeneron抗癌药Zaltrap获FDA批准用于结直肠癌治疗, objectType=article, longId=8590, objectId=583585906e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=583585906e, replyNumber=0, likeNumber=106, createdTime=2013-06-25, rootId=0, userName=axin009, userId=0ad8182, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=583585906e, moduleTitle=赛诺菲及Regeneron抗癌药Zaltrap获FDA批准用于结直肠癌治疗, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=583585906e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Regeneron

2020-05-29

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

赛诺菲（Sanofi）和再生元（Regeneron）撤销关于Libtayo治疗宫颈癌的申请

2022-04-13

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的双抗体鸡尾酒疗法预防新冠病毒COVID-19感染，进入III期研究阶段

2021-01-08

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的COVID-19抗体“鸡尾酒”REGN-COV2可大幅减少病毒载量

2021-08-02

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

抗击新冠在行动：Regeneron宣布与HHS扩大合作，开发针对新型冠状病毒的抗体疗法

2020-09-27

heli0118 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的Inmazeb成为获得FDA批准的埃博拉病毒治疗药物

2021-09-22

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的garetosmab显着降低了肌肉骨化症（"石头人症"）患者的骨骼异常增生

2020-06-21

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron和Vyriad宣布开发新的溶瘤病毒治疗癌症的战略协议

2020-03-09

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

英国NICE批准Sanofi/Regeneron的PD-1单抗Libtayo用于治疗皮肤鳞状细胞癌

2019-11-30

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

赛诺菲/Regeneron的IL-13单抗REGN3500治疗哮喘II期临床试验成功

2019-09-22

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的ANGPTL3单抗evinacumab治疗家族性高胆固醇血症的III期临床成功

2020-04-13

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron的Eylea获得FDA批准治疗糖尿病视网膜病变

2019-09-25

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron和Bluebird Bio强强联手助力于T细胞疗法

2018-11-29

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

美国优先审查Sanofi，Regeneron的cemiplimab。

2018-11-04

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron和Teva的疼痛药物fasinumab被FDA暂时临床搁置

2017-03-20

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

赛诺菲、Regeneron开发PCSK9新药alirocumab临床试验击败Zetia

2015-06-25

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron公司药物Arcalyst扩大应用申请遭FDA拒绝

2012-11-22

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

Regeneron公司单抗药物REGN727稍逊于安进公司药物AMG145

2012-11-03

axin009 (审核中...)

前往app查看评论内容

#Regeneron#

赛诺菲及Regeneron抗癌药Zaltrap获FDA批准用于结直肠癌治疗

2013-06-25

科室
- - 订阅+
  - 更多科室
工具
服务